Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PIK-101
- Development stage
- Unknown
- Lead developer
- Sensei Biotherapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PIK-101 (also known as PIKTOR) is an orally bioavailable small molecule dual inhibitor of the phosphoinositide 3-kinase alpha (PI3Kα) isoform and the mechanistic target of rapamycin complexes 1 and 2 (mTORC1/2). Developed by Faeth Therapeutics, PIK-101 is designed to treat PIK3CA-mutated and pathway-dependent malignancies, specifically hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer. The drug's clinical development is unique in its integration with the Faeth Metabolic Platform, which utilizes a precision insulin-suppressing diet to enhance therapeutic efficacy. By simultaneously blocking PI3Kα and mTORC1/2 while metabolically suppressing insulin, PIK-101 aims to prevent the compensatory insulin feedback loop that typically limits the effectiveness of PI3K inhibitors. It is currently undergoing Phase 1 clinical evaluation.
- Brand names
- PIKTOR
- Other names
- PIKTOR
02
Targets
PIK3CA (Phosphoinositide 3-kinase alpha)Mechanistic target of rapamycin complex 1Mechanistic target of rapamycin kinase complex 2
Beyond the preview
Go deeper on PIK-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PIK-101.